136-150 of 917
Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Project Oncology®Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Parul Rai
Partnering for Better Hypertension Outcomes: How AMA and Azara Support Providers
Perspectives with the AMAPartnering for Better Hypertension Outcomes: How AMA and Azara Support Providers
Charles Turck, PharmD, BCPS, BCCCP
Jeff Brandes
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
On the Frontlines of COPDECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
Raymond Wade, MD
Scaling Success: Hypertension Control at MPCA with the AMA MAP™ Program
Perspectives with the AMAScaling Success: Hypertension Control at MPCA with the AMA MAP™ Program
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Faiyaz Syed MD, MPH
Skin Disease and Cardiovascular Risk: Uncovering a Critical Clinical Connection
On the Frontlines of PsoriasisSkin Disease and Cardiovascular Risk: Uncovering a Critical Clinical Connection
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Joel M. Gelfand, MD, MSCE, FAAD
Michael S. Garshick, MD
Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Heart MattersImproving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
- advertisement
Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Heart MattersEarly Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Rivaroxaban as effective as warfarin for left ventricular thrombus post-MI
ACC Action CenterRivaroxaban as effective as warfarin for left ventricular thrombus post-MI
Anna Bortnick, MD, PhD
Anna Bortnick, MD, PhD
Mobile integrated health program in patients with HF
ACC Action CenterMobile integrated health program in patients with HF
Ruth Masterson Creber, PhD
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC Action CenterPhase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Darren K. McGuire, MD
AI model may accelerate risk stratification of coronary revascularization in ED
ACC Action CenterAI model may accelerate risk stratification of coronary revascularization in ED
Wayne Batchelor, MD
- advertisement
Dapagliflozin reduces worsening HF in elderly TAVI patients
ACC Action CenterDapagliflozin reduces worsening HF in elderly TAVI patients
Wayne Batchelor, MD
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
ACC Action CenterLorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
Gina Lundberg, MD
Gina Lundberg, MD
